The European Medicines Agency on Thursday identified severe allergic reactions as potential side effects of Novavax Inc’s COVID-19 vaccine.
The vaccine was authorized by U.S. regulators on Wednesday, and its product label in the United States warns against administering the shot to people with a history of allergic reactions to any components of the shot.
Shares of Novavax fell 20.3% to $55.72 in morning trading, along with the broader market and other COVID-19 vaccine makers. Novavax shares are usually volatile.
The EMA said it would also update the product information for the vaccine to add unusual or decreased feeling in the skin as a new side effect.
Only 250,000 doses of Novavax’s COVID vaccine, Nuvaxovid, have been administered in Europe so far since its launch in December, according to the European Centre for Disease Prevention and Control.
ALSO READ FROM NIGERIAN TRIBUNE
- Nurse Holds Doctor Hostage In OAU Teaching Hospital, Resident Doctors Plan Strike
- Woman’s Corpse, Unconscious Man Found Inside Office In Aba After Four Days
- Hoodlums Attack Lagos Governor’s Press Crew Bus In Tinubu’s Convoy, Two Injured
- [BREAKING] #EkitiDecides2022: INEC Declares APC’s Biodun Oyebanji Winner Of Guber Poll
- Top 10 Business Ideas In Nigeria You Can Start With 100,000 Naira
- 2023: Kwankwaso Will Not Be Deputy To Obi —NNPP